Clinician’s Update on Omega-3s in ASCVD Risk Reduction

Clinician’s Update on Omega-3s in ASCVD Risk Reduction

Clinician’s Update on Omega-3s in ASCVD Risk Reduction

Our experts tackle questions about the role of fish oil in ASCVD prevention and weigh in on the striking differences between STRENGTH and REDUCE-IT.  

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!

  • Disclosure of Conflicts of Interest

    In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

    Leslie Cho, MD
    Director of Women's Cardiovascular Center
    Cardiovascular Medicine Specialist
    Cleveland Clinic Foundation
    Cleveland, OH

    Consulting & Research/Independent Contractor: Amgen, Novartis Pharmaceuticals
    Consulting: AstraZeneca Pharmaceuticals 

    Erin D. Michos, MD, MHS
    Associate Professor of Medicine and Epidemiology
    Ciccarone Center for the Prevention of Cardiovascular Disease
    Division of Cardiology, Johns Hopkins School of Medicine
    Baltimore, MD

    No relationships reported.

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Sue Grossman has nothing to disclose.
    • Kathy Hoercher, RN, has nothing to disclose.
    • Wael Jaber, MD, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss recent omega-3 fatty acid outcomes trial results and their clinical implications in reducing ASCVD events
    • Explain the biological differences of omega-3 fatty acids EPA and DHA
    • Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, interventional cardiologists, primary care physicians, diabetologists, and endocrinologists.

  • Accreditation and Credit Designation Statements

    The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Cleveland Clinic Foundation Center for Continuing Education designates this internet live activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

    A certificate of attendance will be provided to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

    ReachMD Healthcare Image

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free